BEGIN:VCALENDAR
VERSION:2.0
CALSCALE:GREGORIAN
PRODID:iCalendar-Ruby
BEGIN:VEVENT
CATEGORIES:
DESCRIPTION:Title: The Effectiveness\, Immunogenicity\, and Safety of Mater
 nal Respiratory Syncytial Virus (RSV) Vaccines: A Systematic Review and Met
 a Analysis \n\nIntroduction: Globally\, respiratory syncytial virus (RSV) i
 s responsible for a considerable amount of illness and mortality in elderly
  adults and young children\, with the highest impact in babies born prematu
 rely. Maternal vaccination during pregnancy has been cited as a promising a
 pproach in the prevention of RSV-associated lower respiratory tract infecti
 ons (LRTI) and RSV-associated hospitalizations in infants.\n\nAim: We aimed
  to synthesize randomized controlled trial data and provide a current updat
 e and overview of the efficacy and safety of all available maternal RSV vac
 cines.\n\nMethods: We searched six databases-PubMed\, Embase\, Cochrane Lib
 rary\, Web of Science\, Google Scholar\, and ClinicalTrials.gov until Janua
 ry 15\, 2024\, for all randomized controlled trials (RCTs) that compared ma
 ternal and infant vaccinations against any placebo or a comparator. The met
 a-analysis used RevMan Web software and included six eligible RCTs that eva
 luated maternal RSV vaccine safety\, immunogenicity\, and efficacy in mothe
 rs and their infants.\n\nResults: The analysis included six RCTs on materna
 l RSV vaccines (n = 12\,652 mothers & n = 12\,356 infants). The overall ris
 k of bias and certainty of evidence was low. The findings revealed signific
 ant risk reduction in MA LRTI (RR: 0.50\, 95% CI: 0.35\, 0.71\, p < 0.0001)
  and RSV-related hospitalizations (RR: 0.37\, 95% CI: 0.18\, 0.74\, p = 0.0
 05) in the first 6 months of life. Safety results showed significant differ
 ences in the incidence of adverse events between the two groups (RR: 1.08\,
  95% CI: 1.04\, 1.12\, p < 0.0001). Vaccinated groups were more likely than
  placebo groups to report injection site pain\, swelling\, and erythema. Th
 ere was no significant difference in serious adverse events in infants (RR:
  0.98\, 95% CI: 0.93\, 1.04\, p = 0.52) and maternal participants (RR: 1.05
 \, 95% CI: 0.97\, 1.15\, p = 0.23)\, and in adverse events in infants (RR: 
 1.03\, 95% CI: 0.95\, 1.12\, p = 0.48).\n\nConclusion: Maternal RSV vaccine
 s have a high safety profile and are effective in preventing RSV-associated
  LRTI and RSV-associated hospitalization in infants.\n\nKeywords: Respirato
 ry syncytial virus\, vaccination\, pregnancy\, infants\, safety\, efficacy\
 , meta-analysis\n\nChair: Dr. Ike Okosun
DTEND:20240422T160000Z
DTSTAMP:20260305T210356Z
DTSTART:20240422T150000Z
LOCATION:
SEQUENCE:0
SUMMARY:MPH Thesis Defense: Mahmud Sheku  
UID:tag:localist.com\,2008:EventInstance_46148475963920
URL:https://calendar.gsu.edu/event/mph-thesis-defense-mahmud-sheku
END:VEVENT
END:VCALENDAR